Laurence Albigès, MD, PhD, on the Potential Impact of Immunotherapy-Based Combinations in Advanced RCC

Video

Laurence Albigès, MD, PhD, discusses how immunotherapy combinations have affected the treatment landscape for previously untreated advanced or metastatic renal cell carcinoma.

Laurence Albigès, MD, PhD, a medical oncologist and head of the Genitourinary Unit at Gustave Roussy in Villejuif, who spoke with CancerNetwork® during the 2022 Genitourinary Cancers Symposium highlighted how treatment with immunotherapy-based combinations have had an impact on the treatment landscape for previously untreated advanced or metastatic renal cell carcinoma.

In particular, she referenced the improved overall survival (OS) benefit evident with this treatment strategy across the population, as well as a need for a personalized approaches to treating patients.

Transcript:

The first-line landscape has evolved greatly over time and we now have a standard of care combination approach in all our patients for clear cell RCC in the frontline. What we see is that we are impacting OS in our patients. These trials [involving immunotherapy-based combinations] have changed the landscape and the expected OS benefit for our patients. We moved from a median of about 24 months to now 48 months, if we think about nivolumab plus ipilimumab, [for example]. We have greatly increased the overall survival of our patients. This is impacting our treatment strategy in all countries where we have access to different regimens. We now need to tailor [treatment] a bit more to define what combination is most appropriate for [an individual] patient.

Reference

Tannir NM, Signoretti S, Choueiri TK, et al. Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up. J Clin Oncol. 2022;40(suppl 6):352. doi:10.1200/JCO.2022.40.6_suppl.352

Recent Videos
An “avalanche of funding” has propelled the kidney cancer field forward, says Jason Muhitch, PhD.
Kidney cancer advocacy efforts have spread the urgency and importance of funding research in the field to members of Congress.
Advocacy efforts have yielded a dramatic increase in kidney cancer research, according to Elizabeth P. Henske, MD.
A review of patients with metastatic clear cell renal cell carcinoma shows radiological tumor burden as an independent prognostic factor for survival.
A phase 2 trial is assessing ubamatamab in patients with MUC16-expressing SMARCB1-deficient renal medullary carcinoma and epithelioid sarcoma.
Analysis of 2 phase 1 trials compared gut biome diversity between standard of care with or without CBM588 in patients with metastatic renal cell carcinoma.
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Related Content